REGENXBIO Inc. (RGNX)
RGNX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$7.26
-6.56% on the day
Market cap
$479.3M
Small cap
Revenue · 2025
$170.4M
+104.5% on 2024
Net income · 2025
-$193.9M
-113.8% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | RGNX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001590877 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $170.4M |
| Net income | -$193.9M |
| Operating income | -$161.2M |
| Net margin | -113.8% |
| Operating margin | -94.6% |
| Revenue growth | +104.5% |
| Cash | $34.5M |
| Total assets | $453.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.8× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-07-17 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-09-23 |
| Latest proxy | DEFA14A | 2026-04-14 |
Source: SEC EDGAR submissions feed, 798 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -10.1% |
| 1 month | -14.0% |
| 3 months | -39.0% |
| Year to date | -52.6% |
| 1 year | -39.8% |
| From 52-week high | -57.3% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PROK | ProKidney Corp. | $1.57 | -5.99% | $474.6M |
| ALLO | Allogene Therapeutics Inc. | $1.29 | -7.86% | $445.7M |
| VALN | Valneva SE | $5.56 | -6.24% | $527.6M |
| AGMB | AgomAb Therapeutics NV | $8.81 | -3.08% | $433.9M |
| ENTX | Entera Bio Ltd. | $2.49 | -6.04% | $433.1M |
| AUTL | Autolus Therapeutics plc American Depositary Share | $1.62 | -6.90% | $431.2M |
| DBVT | DBV Technologies S.A. | $9.03 | -5.45% | $534.7M |
| ETRA | Electra Therapeutics Inc. | $8.61 | -7.62% | $540.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier